Saurabh Kataria

Dr. Saurabh Kataria

Department of Neurology, University of Missouri Healthcare at Columbia, MO
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2021 in Cureus
Verified
Journal Article
Open access
SSSobia Sarwar
Sobia Sarwar
AMAlaa S. Mohamed
Alaa S. Mohamed
SRSylvette Rogers
Sylvette Rogers
SSShah T. Sarmast
Shah T. Sarmast
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
RSRomil Singh
Romil Singh
Patients with systemic lupus erythematosus (SLE) experience neuropsychiatric symptoms. The term neuropsychiatric SLE (NPSLE) is a generic term that refers to a series of neurological and psychiatric symptoms directly related to SLE. In approximately 30% of patients with neuropsychiatric symptoms, SLE is the primary cause (NPSLE), and symptoms manifest more frequently around SLE onset. Neurovascular and psychotic conditions can also lead to NPSLE. Pathogenesis of NPSLE is implicated in both neuroinflammatory and ischemic mechanisms, and it is associated with high morbidity and mortality. After diagnosing and assigning causality, NPSLE treatment is individualized according to the type of neuropsychiatric manifestations, type of the predominant pathway, activity of SLE, and severity of the clinical manifestations. There are many problems to be addressed with regards to the diagnosis and management of NPSLE. Controlled clinical trials provide limited guidance for management, and observational cohort studies support symptomatic, antithrombotic, and immunosuppressive agents. The purpose of this review was to provide a detailed and critical review of the literature on the pathophysiology, diagnosis, and treatment of NPSLE. This study aimed to identify the shortcoming in diagnostic biomarkers, novel therapies against NPSLE, and additional research needs.

12 October 2020 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
SSShitiz Sriwastava
Shitiz Sriwastava
MTMedha Tandon
Medha Tandon
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
MDMaha Daimee
Maha Daimee
SSShumaila Sultan
Shumaila Sultan

1 January 2021 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
SSShitiz Sriwastava
Shitiz Sriwastava
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
MTMedha Tandon
Medha Tandon
JPJenil Patel
Jenil Patel
RPRiddhi Patel
Riddhi Patel
RLRobert P. Lisak
Robert P. Lisak

1 March 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MTMedha Tandon
Medha Tandon
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
JPJenil Patel
Jenil Patel
TMTejas R Mehta
Tejas R Mehta
MDMaha Daimee
Maha Daimee
SSShitiz Sriwastava
Shitiz Sriwastava
Limited literature exists on Cerebrospinal fluid (CSF) findings in COVID-19 patients with neurological symptoms. In this review, we conducted a descriptive analysis of CSF findings in patients with COVID-19 to understand prognosis and explore therapeutic options. We searched PubMed, Google Scholar, and Scopus databases using the keywords "SARS-CoV-2 in cerebrospinal fluid" and "SARS-CoV-2 and CNS Complications" for reports of CSF findings in COVID-19 related neurological manifestations. Descriptive analyses were conducted to observe the CSF protein and cell counts based on age, gender, severity, fatality of COVID-19, and whether central (CNS) or peripheral nervous system (PNS) was associated. A total of 113 patients were identified from 67 studies. Of these, 7 patients (6.2%) were fatal COVID-19 cases and 35 patients (31%) were considered severe COVID-19 cases. CSF protein was elevated in 100% (7/7) of the fatal cases with an average of 61.28 mg/dl and in 65.0% (52/80) in non-fatal cases with an average 56.73 mg/dl. CSF protein levels were elevated in 74.5% (38/51) patients with non-severe COVID-19 and 68.6% (24/35) in those with a severe COVID-19 infection. CSF cell count was increased in 43% of fatal cases, 25.7% severe cases, and 29.4% of non-severe cases. Our analysis showed that the most common CSF findings situation in COVID-19 infection is elevated protein with, very occasionally, mild lymphocyte predominant pleocytosis. Further studies to elucidate the pathophysiology of neurological complications in COVID-19 are recommended.

13 July 2020 in Cureus
Verified
Journal Article
Open access
PDF file
Saurabh KatariaSaurabh Kataria
Saurabh Kataria
ASAftab Sharif
Aftab Sharif
ARAsad Ur Rehman
Asad Ur Rehman
ZAZahoor Ahmed
Zahoor Ahmed
AHAbdul Hanan
Abdul Hanan
A 49-year-old female with no history of past medical illness presented to the emergency department with complaints of fever, dry cough, and shortness of breath. Initial evaluation revealed a temperature of 101°F, and on auscultation, the patient had scattered wheezing and rales in left lung fields. CT of the chest revealed pneumonic patches in the upper and lower segment of the left lung. Her COVID-19 testing came positive. On the second day of hospital admission, the patient experienced nausea, vomiting, and severe epigastric pain radiating to back. Laboratory analysis revealed a marked elevation of lipase and amylase. CT of the abdomen showed an edematous pancreas with diffuse enlargement. She was diagnosed with acute pancreatitis due to COVID-19 after carefully ruling out other causes. She was managed symptomatically, and improvement in her clinical condition was observed and was discharged with outpatient follow-up. Although acute pancreatitis is rare in patients with COVID-19, it should be considered as a differential diagnosis in patients with severe epigastric pain and respiratory symptoms.

3 April 2021 in Cureus
Verified
Journal Article
Open access
TMTrishala Menon
Trishala Menon
SGSaad Abdul Quddus Gandhi
Saad Abdul Quddus Gandhi
WTWarisha Tariq
Warisha Tariq
RSRohit Sharma
Rohit Sharma
SSSundus Sardar
Sundus Sardar
RSRomil Singh
Romil Singh
Coronavirus disease 19 (COVID-19) has affected over 180 countries, resulting in global mass death. It has been reported that patients with underlying disease are more likely to contract the disease and become critically ill. The impact of chronic kidney disease (CKD) on the severity of COVID-19 has been underlined in the literature. In this analysis, we have provided evidence of an association between CKD and COVID-19. We followed the PRISMA protocol and conducted a literature search using Google Scholar, EMBASE, PubMed, and Clinical trail.gov. The initial search yielded 2102 articles. We included 20 cohorts based on inclusion criteria reporting an association between CKD and COVID-19 after excluding irrelevant articles, including review articles and duplicates. We conducted pooled prevalence of CKD and meta-analysis to estimate the odds ratio (OR), 95% confidence interval (CI) using Cochrane RevMan (version 5.4, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration), and R programming language version 4.16-2 (University of Auckland, New Zealand). Our study involved 4350 patients from different countries, and 212 (4.9%) patients had CKD. Among 20 cohorts, 57.27% were male with a median age of 55.5 years. Eight hundred sixty-six patients developed severe COVID-19, and out of which, 39 (4.5%) were CKD patients. CKD patients had a significantly increased risk of severe disease as compared to non-CKD patients with a pooled OR of 2.15 (95% CI 1.16-4.01) (I2=41; p=0.02). Out of 443 COIVD-19 patients who died, 85 patients had CKD, with a prevalence of 19.18%. CKD patients had an increased risk of death as compared to non-CKD patients with a pooled OR of 5.58 (95% CI 3.27-9.54) (I2=0; p<0.00001). CKD is manifested as a common underlying disease in COVID-19 patients who had a worse prognosis, including mortality.